NCT03284710: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 2 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03284710 |
|---|---|
| Title | A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 19, 2017 |
| Completion date | Dec. 12, 2019 |
| Required reporting date | Dec. 11, 2020, midnight |
| Actual reporting date | Dec. 14, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 2 |